牛皮癣是一种慢性炎症性疾病，有时需要使用生物制剂进行治疗干预。肿瘤坏死因子 (TNF) 抑制剂治疗期间产生自身抗体是公认的现象，然而，与抗磷脂综合征 (APS) 相关的自身抗体的产生尚未在银屑病患者中得到全面评估。本研究旨在评估接受不同生物制剂治疗的银屑病患者中 APS 相关自身抗体的患病率，并调查自身抗体产生与临床或血清学参数之间的潜在关联。接受生物制剂治疗的银屑病患者被纳入本研究，并根据所施用的生物制剂类型、TNF、白细胞介素 (IL)-17 或 IL-23 抑制剂进行分类。收集临床和血清学数据并结合 APS 自身抗体数据进行分析。与 IL-17 和 IL-23 抑制剂相比，TNF 抑制剂与更高频率的 APS 自身抗体相关。值得注意的是，在接受 TNF 抑制剂治疗的患者中，APS 自身抗体的存在与并发关节炎和治疗开始时较高的疾病严重程度相关。银屑病面积和严重程度指数评分升高以及抗核抗体滴度高于 × 320是APS自身抗体产生的预测因素。尽管自身抗体率较高，但这些患者没有出现 APS 的临床症状。这项研究提供了第一个全面的证据，证明银屑病患者中 APS 自身抗体的频率增加与 TNF 抑制剂治疗相关。观察到的 APS 自身抗体阳性与 TNF 抑制剂治疗或临床参数之间的关联表明，在银屑病发病机制中，自身免疫和炎症之间存在潜在的免疫调节相互作用。© 2024。作者。

Psoriasis is a chronic inflammatory disease that sometimes necessitates therapeutic intervention with biologics. Autoantibody production during treatment with tumor necrosis factor (TNF) inhibitors is a recognized phenomenon, however, the production of autoantibodies associated with antiphospholipid syndrome (APS) has not been comprehensively evaluated in patients with psoriasis. This study was conducted to assess the prevalence of APS-associated autoantibodies in patients with psoriasis treated with different biologics and to investigate the potential associations between autoantibody production and clinical or serological parameters. Patients with psoriasis undergoing biologics treatments were enrolled in this study, and were categorized based on the type of biologics administered, TNF, interleukin (IL)-17, or IL-23 inhibitors. Clinical and serological data were collected and analyzed in conjunction with data on APS autoantibodies. TNF inhibitors were associated with a higher frequency of APS autoantibodies compared to IL-17 and IL-23 inhibitors. Notably, the presence of APS autoantibodies correlated with concurrent arthritis and higher disease severity at treatment initiation in patients treated with TNF inhibitors. Elevated Psoriasis Area and Severity Index scores and anti-nuclear antibody titers higher than × 320 were predictors of APS autoantibody production. Despite the higher autoantibody rates, clinical symptoms of APS were absent in these patients. This study provides the first comprehensive evidence of an increased frequency of APS autoantibodies associated with TNF inhibitor treatment in patients with psoriasis. The observed association between APS autoantibody positivity and TNF inhibitor treatment or clinical parameters suggests a potential immunomodulatory interplay between autoimmunity and inflammation in the pathogenesis of psoriasis.© 2024. The Author(s).